Q-omics provides the consensus-scored UBE4B profile across patient tissues and cancer cell-line models. UBE4B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE4B is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, UBE4B RNA expression shows 20,666 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUSC as cancer lineages where UBE4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE4B survival associations across molecular data types. UBE4B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE4B RNA expression–survival associations across cancer types. High UBE4B expression shows unfavorable associations in ACC, LUSC, BLCA and LIHC, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE4B RNA expression.
This table summarizes UBE4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBE4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE4B shows lower tumor expression in THCA and KICH and higher tumor expression in LUSC, LIHC, HNSC and CHOL. The LUSC box plot shows higher UBE4B RNA expression in tumor versus normal tissue (log2 FC = +0.911, t-test p < 0.001).
This table shows molecular features associated with UBE4B in patient tissues and cancer cell lines. In patient samples, UBE4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
